A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes

Boyle, Luke D and Wilding, John PH ORCID: 0000-0003-2839-8404 (2014) A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes. EXPERT OPINION ON DRUG SAFETY, 13 (11). pp. 1535-1544.

Text Canagliflozin Draft LB_070414 JWcomments.docx - Unspecified Download (180kB)

Abstract

<h4>Introduction</h4>Numerous treatments are available for type 2 diabetes mellitus (T2DM), which can improve insulin sensitivity or stimulate its secretion. These are usually unable to halt progression. Inhibition of glucose reabsorption from the renal filtrate was proposed as a novel therapeutic target. Sodium/glucose co-transporter 2 (SGLT2) inhibitors were developed accordingly, with canagliflozin the first to launch in the US in 2013.<h4>Areas covered</h4>The mechanism of action of canagliflozin, its pharmacokinetic data and its clinical applications and efficacy data from clinical studies of both subjects with T2DM controlled on diet and exercise, and those on glucose-lowering agents and insulin. The evaluation focuses primarily on the safety of canagliflozin in clinical trials conducted for initial registration due to limited post-marketing data, discusses safety in special populations, before comparing its safety with existing therapies.<h4>Expert opinion</h4>Canagliflozin offers a novel therapeutic approach to T2DM; advantages include weight loss and blood pressure lowering with a low intrinsic risk of hypoglycaemia. The main adverse effects likely to be seen are a very small increase in risk of urinary tract infections and a modest risk of developing genital fungal infections. Studies suggest no increased risk of cardiovascular (CV) disease, but longer duration outcome studies are essential.

Item Type:	Article
Uncontrolled Keywords:	canagliflozin, safety, sodium/glucose co-transporter 2, type 2 diabetes
Depositing User:	Symplectic Admin
Date Deposited:	19 Oct 2015 08:35
Last Modified:	19 Oct 2023 09:50
DOI:	10.1517/14740338.2014.959488
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/2032259